BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects. 1995

R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Department of Pharmacology and Toxicology, University of Alabama at Birmingham 35294-0019, USA.

Human pharmacokinetics of an antisense oligodeoxynucleotide phosphorothioate (GEM 91) developed as an anti-human immunodeficiency virus (HIV) agent was carried out in this study. 35S-Labeled GEM 91 was administered to six HIV-infected individuals by means of 2-hour intravenous infusions at a dose of 0.1 mg/kg. Plasma disappearance curves for GEM 91-derived radioactivity could be described by the sum of two exponentials, with half-life values of 0.18 +/- 0.04 and 26.71 +/- 1.67 hours. The radioactivity in plasma was further evaluated by polyacrylamide gel electrophoresis, showing the presence of both intact GEM 91 and lower molecular weight metabolites. Urinary excretion represented the major pathway of elimination, with 49.15% +/- 6.80% of the administered dose excreted within 24 hours and 70.37% +/- 6.72% over 96 hours after dosing. The radioactivity in urine was associated with lower molecular weight metabolites. No drug-related toxicity was observed.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA
D013462 Sulfur Radioisotopes Unstable isotopes of sulfur that decay or disintegrate spontaneously emitting radiation. S 29-31, 35, 37, and 38 are radioactive sulfur isotopes. Radioisotopes, Sulfur

Related Publications

R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects.
January 1999, Journal of clinical pharmacology,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
March 1995, Biochemical pharmacology,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Inhibition of human immunodeficiency virus type 1 (HIV) gag gene expression by an antisense oligodeoxynucleotide phosphorothioate.
October 1995, Leukemia,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.
May 1997, AIDS research and human retroviruses,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
GEM 91--an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS.
January 1992, Antisense research and development,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.
June 1989, Proceedings of the National Academy of Sciences of the United States of America,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
January 1994, Antisense research and development,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
August 1994, Proceedings of the National Academy of Sciences of the United States of America,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.
May 1997, Antimicrobial agents and chemotherapy,
R Zhang, and J Yan, and H K Shahinian, and H Shahinian, and G Amin, and Z Lu, and T Liu, and M S Saag, and Z Jiang, and J Temsamani, and R R Martin
Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
January 1994, Oncology research,
Copied contents to your clipboard!